Would like to see the details that come out of the Investor Briefing, before judging too much. From the Appendix4C it looks like a fairly big jump on the last quarter for administration and corporate costs, and a fairly insignificant sum spent on marketing. Understand they have self marketed a bit through news interviews etc and have been selling b2b but $9000..... seems quite paltry when they are selling HIV tests direct to the public. A more positive view would be they are saving using partner organisations to move product but a breakdown of where sales are coming from would be nice.
These are my views/opinions only please do your own research
Ann: Appendix 4C - 31 December 2021, page-4
-
- There are more pages in this discussion • 23 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AT1 (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
2.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $15.98M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 173214 | 2.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.6¢ | 37953 | 1 |
View Market Depth
| Last trade - 10.00am 24/07/2024 (20 minute delay) ? |
| AT1 (ASX) Chart |
Day chart unavailable